Efficacy of ozoralizumab in rheumatoid arthritis patients with large joint involvement: a post hoc analysis of OHZORA and NATSUZORA trials
Authors' conclusion
Ozoralizumab has the potential to improve disease activity and physical dysfunction and prevent joint destruction in patients, regardless of the presence of LJI, and is a reasonable treatment option, even for patients with LJI.
Study context
- Population
- Japanese patients with rheumatoid arthritis (RA) who received ozoralizumab 30 mg every 4 weeks for 52 weeks in OHZORA (with concomitant MTX) and NATSUZORA (without concomitant MTX)OHZORA 152
- Comparison
- RA with vs without large joint involvement, on ozoralizumab 30 mg every 4 weeks
Methodological detailssubgroup analysis, OHZORA: 111 with large joint involvement (LJI), 41 without LJI; NATSUZORA: 72 with LJI, 22 without LJI
- Subgroup analysis
- OHZORA: 111 with LJI, 41 without LJI; NATSUZORA: 72 with LJI, 22 without LJI
Primary result
As reported in the abstract
Disease activity (CDAI)
- Baseline CDAI significantly higher with LJI than without LJI; difference not present as early as day 3 of ozoralizumab and at most subsequent assessments
- Similar trend for patient-reported/physician-reported outcomes and HAQ
- Blood IL-6 and MMP-3 levels in patients with LJI continuously decreased during treatment
- Changes in mTSS at week 24 similar between the groups (OHZORA)
- Completion rates did not differ significantly between the groups
- Post hoc analysis
Original publication
Efficacy of ozoralizumab in rheumatoid arthritis patients with large joint involvement: a post hoc analysis of OHZORA and NATSUZORA trials. RMD Open. Published 11 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →